Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)

GSK Investigational Site, Sofia

GSK Investigational Site, Sofia

GSK Investigational Site, Plovdiv

GSK Investigational Site, Ghent

GSK Investigational Site, Bangkok

GSK Investigational Site, Genoa

GSK Investigational Site, Bielefeld

GSK Investigational Site, Khon Kaen

GSK Investigational Site, Bologna

GSK Investigational Site, Dnipro

GSK Investigational Site, Pisa

GSK Investigational Site, Torrette Di Ancona

GSK Investigational Site, Odesa

GSK Investigational Site, Strasbourg

GSK Investigational Site, Oleksandrivka Village, Odesa

GSK Investigational Site, Foggia

GSK Investigational Site, Limoges

GSK Investigational Site, Luhansk

GSK Investigational Site, Moscow

GSK Investigational Site, Moscow

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Belgorod

GSK Investigational Site, Krasnodar

GSK Investigational Site, Kazan'

GSK Investigational Site, Samara

GSK Investigational Site, Rome

GSK Investigational Site, Rome

GSK Investigational Site, Heemstede

GSK Investigational Site, Warsaw

GSK Investigational Site, Smolensk

GSK Investigational Site, Poltava